Support Line: 0800 002 9002
General Enquiries: 01223 870008


News Archive

Nivolumab

MHRA authorises cancer treatment variation with an administration time of 3–5 minutes

MHRA authorises cancer treatment variation with an administration time of 3–5 minutes

On 30 April 2025, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved a new under-the-skin ...
Cabo + nivo & ipi delays kidney cancer progression

Cabo + nivo & ipi delays kidney cancer progression

Adding cabozantinib (Cabometyx) to nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival ...
Kidney Cancer UK represents patients at NICE nivo+ipi appraisal

Kidney Cancer UK represents patients at NICE nivo+ipi appraisal

On 3rd February 2022, NICE approve the use of nivolumab with ipilimumab as a first line treatment for kidney ...
No results found.